Skip to main content
SpringerLink
Log in

Adalimumab/infliximab

Infusion reaction and dermatological side effects: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Pouillon L, et al. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. Inflammatory Bowel Diseases 25: 945-954, No. 5, May 2019. Available from: URL: http://doi.org/10.1093/ibd/izy322 - France

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/infliximab. Reactions Weekly 1768, 28 (2019). https://doi.org/10.1007/s40278-019-66713-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-66713-9

Search

Navigation